Suppr超能文献

肝内胆管癌的分子诊断

Molecular diagnosis of intrahepatic cholangiocarcinoma.

作者信息

Haga Hiroaki, Patel Tushar

机构信息

Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

出版信息

J Hepatobiliary Pancreat Sci. 2015 Feb;22(2):114-23. doi: 10.1002/jhbp.156. Epub 2014 Sep 29.

Abstract

Intrahepatic cholangiocarcinomas (iCCA) are primary intrahepatic malignancies originating from biliary epithelia. While both hepatocellular cancer and iCCA can present as mass lesions within the liver, these cancers are distinct in their morphology, etiology, pathology, natural history and response to therapy. There is a need for accurate and sensitive molecular markers for the diagnosis of iCCA. Recent advances in elucidating molecular and genetic characteristics of iCCA offer the potential of molecular-based diagnosis of iCCA. Specific genetic mutations of IDH1/2, BAP1, p53, and KRAS, FGFR gene fusions and alterations in microRNA have all been described in iCCA. Although there are no accurate serum or biliary biomarkers currently available for diagnosis of iCCA, several potential candidates have been identified. Knowledge of specific genetic or molecular abnormalities offers potential for individualized approaches for the treatment of patients with iCCA in the future.

摘要

肝内胆管癌(iCCA)是起源于胆管上皮的原发性肝内恶性肿瘤。虽然肝细胞癌和iCCA都可表现为肝脏内的肿块病变,但这些癌症在形态、病因、病理、自然史和对治疗的反应方面有所不同。需要准确且敏感的分子标志物来诊断iCCA。在阐明iCCA分子和遗传特征方面的最新进展为基于分子的iCCA诊断提供了潜力。IDH1/2、BAP1、p53和KRAS的特定基因突变、FGFR基因融合以及微小RNA的改变在iCCA中均有描述。尽管目前尚无准确的血清或胆汁生物标志物可用于诊断iCCA,但已确定了几种潜在的候选标志物。了解特定的基因或分子异常为未来iCCA患者的个体化治疗方法提供了潜力。

相似文献

1
Molecular diagnosis of intrahepatic cholangiocarcinoma.
J Hepatobiliary Pancreat Sci. 2015 Feb;22(2):114-23. doi: 10.1002/jhbp.156. Epub 2014 Sep 29.
2
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Clin Mol Hepatol. 2022 Jul;28(3):396-407. doi: 10.3350/cmh.2021.0287. Epub 2022 Jan 14.
3
Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis.
Surg Oncol. 2017 Jun;26(2):125-137. doi: 10.1016/j.suronc.2016.12.009. Epub 2017 Feb 20.
4
Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Hum Pathol. 2023 Feb;132:197-207. doi: 10.1016/j.humpath.2022.06.001. Epub 2022 Jun 11.
5
Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15.
6
[Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
Pathologe. 2020 Sep;41(5):488-494. doi: 10.1007/s00292-020-00808-6.
8
Pathology of Cholangiocarcinomas.
Curr Oncol. 2022 Dec 26;30(1):370-380. doi: 10.3390/curroncol30010030.
9
Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Histopathology. 2021 Jan;78(2):310-320. doi: 10.1111/his.14222. Epub 2020 Sep 15.
10
Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.
Cancer Res Commun. 2023 Mar 6;3(3):383-394. doi: 10.1158/2767-9764.CRC-22-0422. eCollection 2023 Mar.

引用本文的文献

3
Telomeres and Telomerase in the Development of Liver Cancer.
Cancers (Basel). 2020 Jul 24;12(8):2048. doi: 10.3390/cancers12082048.
5
Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure.
Clin Proteomics. 2019 Oct 30;16:37. doi: 10.1186/s12014-019-9257-x. eCollection 2019.
6
7
Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
Virchows Arch. 2019 Jan;474(1):29-37. doi: 10.1007/s00428-018-2478-y. Epub 2018 Oct 30.
8
The role of microRNAs in intrahepatic cholangiocarcinoma.
J Cell Mol Med. 2017 Jan;21(1):177-184. doi: 10.1111/jcmm.12951. Epub 2016 Sep 13.
9
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.
Medicine (Baltimore). 2016 Jan;95(2):e2491. doi: 10.1097/MD.0000000000002491.
10
Targeted Therapy in Biliary Tract Cancers.
Curr Treat Options Oncol. 2015 Oct;16(10):48. doi: 10.1007/s11864-015-0366-0.

本文引用的文献

1
Extracellular vesicle noncoding RNA: new players in the diagnosis and pathogenesis of cholangiocarcinoma.
Hepatology. 2014 Sep;60(3):782-4. doi: 10.1002/hep.27185. Epub 2014 Jun 20.
2
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Curr Opin Gastroenterol. 2014 May;30(3):295-302. doi: 10.1097/MOG.0000000000000050.
3
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.
5
Genomic and transcriptional alterations of cholangiocarcinoma.
J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):380-7. doi: 10.1002/jhbp.67. Epub 2014 Feb 13.
6
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis.
Hepatology. 2014 Sep;60(3):896-907. doi: 10.1002/hep.27050. Epub 2014 Jul 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验